Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Biogen Inc

BIIB ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$209.83

▼ -0.39%

Market Cap $31.00B · Vol 225.68K

Key Metrics

P/E Ratio

37.16

FWD: 14.04

Market Cap

$31.00B

Large Cap

Div Yield

N/A

EPS Growth

-18.76%

YoY

RSI (14)

62.56

Momentum

Beta

0.17

vs Market

52W High

$219.20

4.27% below

52W Low

$131.54

59.52% above

Volume

225.68K

Avg 447.33K

P/B

1.41

Price-to-book

ROE

12.85%

Return on equity

Free Float

99.75%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Biogen Inc (BIIB) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BIIB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.91%

+9.31%

+9.65%

+6.77%

YTD

+19.23%

+55.50%

-22.35%

-38.69%

Financials & Valuation

TTM · Annual

Total Revenue	$9.89B
Net Income	$1.29B
Revenue Growth (YoY)	+3.42%
Gross Margin	70.86%
Operating Margin	28.48%
Net Profit Margin	13.07%
ROE	12.85%
ROA · ROIC	5.41% · 6.37%

P/E Ratio	37.16
Forward P/E (FY1)	14.04
PEG Ratio	-0.93
P/S	2.62
P/B	1.41
P/FCF	12.82
EPS Growth	-18.76%
Outstanding Shares	147.75M

Technical Indicators

50-Day SMA	$203.34
200-Day SMA	$186.38
RSI (14)	62.56
Beta	0.17
52-Week High	$219.20
52-Week Low	$131.54

Volume Today	225.68K
Avg Daily Volume (30D)	447.33K
Relative Volume	0.50x
Volatility (10D)	22.60
Volatility (30D)	42.93
Free Float	99.75%

Analyst Consensus

BUY

Current Price $209.83

Mean Target $237.76

52W Low$131.54 52W High$219.20

Current

Target

$131.54 $219.20

Current Analyst target

+13.31% upside potential · 38 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S67826

ISINUS09062X1037

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% INCY Incyte Corp -0.30%

Company Profile

Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.